PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542874
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542874
Global Alzheimer's Disease (AD) Therapeutics Market - 2024-2031
Overview
Global Alzheimer's Disease (AD) Therapeutics Market reached US$ 3,600 million in 2023 and is expected to reach US$ 7,829 million by 2031, growing at a CAGR of 10.2% during the forecast period 2024-2031
Alzheimer's Disease is a neurological disorder affecting older adults, causing deterioration in memory, thinking, and behavior. It is the most common cause of dementia, a severe cognitive decline that interferes with daily life. The disease is caused by the accumulation of amyloid plaques and tau tangles in the brain, disrupting normal function. As the disease progresses, individuals may experience confusion, mood swings, and difficulty performing daily tasks.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of Alzheimer's diseases
The global Alzheimer's disease therapeutics market is growing due to the increasing prevalence of the disease, particularly in developed countries with higher life expectancies. This has led to a greater demand for effective treatment options, driving research and development in the field.
For instance, according to an article published in NCBI 2023, over 25 million people worldwide are affected by dementia, primarily Alzheimer's disease. The cause is still unknown, but evidence suggests that vascular risk factors and disorders, such as smoking, high blood pressure, obesity, diabetes, and cerebrovascular lesions, and psychosocial factors like education, social engagement, and physical exercise, may play a role in the pathogenetic process and clinical manifestation of dementia.
Long-term interventions focusing on controlling multiple vascular risk factors and maintaining socially integrated lifestyles and mentally stimulating activities are expected to reduce the risk or delay the clinical onset of dementia, including Alzheimer's disease.
Regulatory hurdles
The global Alzheimer's disease therapeutics market faces challenges such as high failure rates in clinical trials, the complexity of the disease, regulatory hurdles, and high costs. The lack of accessibility in low- and middle-income countries and the high cost of existing treatments further limit the market's growth, despite the increasing demand driven by the disease's prevalence.
Market Segment Analysis
The global Alzheimer's disease therapeutics market is segmented based on drug class, route of administration, distribution channel, and region.
The cholinesterase inhibitors from the drug class segment accounted for approximately 43.3% of the alzheimer's disease (AD) therapeutics market share
The cholinesterase inhibitors from the drug class segment accounted for approximately 43.3%. Cholinesterase inhibitors are a key component in the global Alzheimer's disease (AD) therapeutics market, enhancing cognitive function and memory in mild to moderate AD patients. These drugs, like donepezil, rivastigmine, and galantamine, increase acetylcholine levels, a neurotransmitter typically reduced in AD patients.
Although they do not cure the disease or halt its progression, they provide symptomatic relief, improving patient quality of life and easing caregiver burden. The global market for cholinesterase inhibitors is significant due to their efficacy, availability, and ongoing need for symptomatic AD management. However, the development of new, more effective therapies may impact their market share in the future.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to its high prevalence and access to excellent hospitals and research centers. The FDA and Health Canada ensure the safety and effectiveness of Alzheimer's drugs. The region's significant healthcare spending and support from patient-focused groups contribute to the overall success of Alzheimer's research and treatment.
For instance, in July 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Market Segmentation
By Drug Class
Cholinesterase Inhibitors
Donepezil
Galantamine
Rivastigmine
NMDA Receptor Antagonists
Manufactured Combination
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Eli Lilly and Company, Biogen Inc., AstraZeneca PLC, Roche Holding AG, Novartis International AG, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc., H. Lundbeck A/S among others.
Key Developments
In June 2024, Eisai and Biogen launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody "LEQEMBI" in China, approved in January 2024 for treating mild cognitive impairment due to Alzheimer's disease and mild AD dementia. China is the third country to launch LEQEMBI, following the United States and Japan.
Why Purchase the Report?
To visualize the global Alzheimer's disease (AD) therapeutics market segmentation based on drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the Alzheimer's disease (AD) therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global Alzheimer's disease (AD) therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Drug Class
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rise in the prevalence of Alzheimer's Disease
- 4.1.1.2. Advancements in the treatment options
- 4.1.2. Restraints
- 4.1.2.1. Regulatory hurdles
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. PESTLE Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Drug Class
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 6.1.2. Market Attractiveness Index, By Drug Class
- 6.2. Cholinesterase Inhibitors *
- 6.2.1. Introduction
- 6.3. NMDA Receptor Antagonists
- 6.4. Manufactured Combination
- 6.5. Others
7. By Route of Administration
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Parenteral
8. By Distribution Channel
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies
9. By Region
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.6.1. The U.S.
- 9.2.6.2. Canada
- 9.2.6.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.6.1. Germany
- 9.3.6.2. UK
- 9.3.6.3. France
- 9.3.6.4. Italy
- 9.3.6.5. Spain
- 9.3.6.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.6.1. Brazil
- 9.4.6.2. Argentina
- 9.4.6.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.6.1. China
- 9.5.6.2. India
- 9.5.6.3. Japan
- 9.5.6.4. South Korea
- 9.5.6.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
11. Company Profiles
- 11.1. Eli Lilly and Company*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
- 11.2. Biogen Inc.
- 11.3. AstraZeneca PLC
- 11.4. Roche Holding AG
- 11.5. Novartis International AG
- 11.6. Johnson & Johnson
- 11.7. Merck & Co., Inc.
- 11.8. Pfizer Inc.
- 11.9. Amgen Inc.
- 11.10. H. Lundbeck A/S (*LIST NOT EXHAUSTIVE)
12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
